BIS Certification
CDSCO
CPCB
LMPC
WPC Approval
Global Approvals
TEC
ARAI
BEE
ISO Certification
Drone Registration
NOC For Steel
Business Registration
Legal Services
Trademark Registration
Copyright Registration
Patent Registration
- The cdsco new drug approval process is governed by the New Drugs and Clinical Trials Rules, 2019 (NDCTR).
- Success depends on dossier completeness, bridging data for Indian populations, and early regulator engagement.
- Form 44 remains the key submission format for most new drug and biologic applications.
- Clear manufacturing documentation, GMP alignment, and BIS-quality compliance reduce review queries.
- Post-approval pharmacovigilance and real-world safety reporting are mandatory for all approved new drugs.
Understanding the cdsco new drug approval process in India
In 2024, a Hyderabad-based pharma start-up approached our firm after facing a six-month delay in CDSCO review. Their dossier was technically strong but lacked clarity on Indian clinical bridging and CMC comparability. Once we mapped their data to CDSCO’s expectations, the approval moved in under four months.
That story reflects a common challenge: even well-prepared pharma teams often misjudge what Indian regulators prioritise. The cdsco new drug approval process is not only about having good science—it’s about aligning documentation with the way CDSCO reads and decides.
The Central Drugs Standard Control Organisation (CDSCO) functions under the Directorate General of Health Services, Ministry of Health & Family Welfare. It regulates the import, manufacture, and marketing of drugs across India.
Legal framework: NDCTR 2019 and CDSCO’s role in regulating new drugs
The backbone of new medicine regulatory in India is the New Drugs and Clinical Trials Rules (NDCT), 2019, underpinned from the Drugs and Cosmetics Act of 1940. These rules provide updates to the approval, clinical trial process, and ethics requirements.
Under the NDCT, the Central Drug Standard Control Organization (CDSCO) reviews each new drug at the application stage, utilizing the office of the Drugs Controller General of India (DCGI). The authority is responsible for ensuring that a product’s safety, efficacy, and quality is established prior to allowing market authorisation.
For context, NDCT brings India into alignment with ICH-like principles such as those utilised in Canada or the EU, and ultimately enhances predictability for global innovators and the regulatory review process. CDSCO, separately, has committed to releasing periodic notifications to help clarify the expectations for timelines and documentation requirements—we recommend that applicants stay updated with CDSCO notifications to ensure accurate and up-to-date applications.
What qualifies as a “new drug” under CDSCO regulations?
A common misconception is that only new chemical entities (NCEs) need cdsco new drug approval. In fact, several product categories qualify:
- New molecules or chemical entities not previously approved in India.
- New dosage forms or routes of administration (e.g., transdermal, inhalation).
- New combinations of previously approved drugs.
- Modified release formulations with new pharmacokinetic profiles.
- Biologics, biosimilars, or vaccines with new manufacturing processes.
- Imported drugs approved in other countries but untested in Indian populations.
Even a minor change in strength or indication can reclassify a product as a “new drug” under CDSCO norms. Identifying this early saves months in re-filing.
Step-by-step process for cdsco new drug approval
The cdsco new drug approval pathway can be visualised as five major stages:
- Pre-submission preparation and strategy
- Filing of Form 44 and dossier submission
- Scientific and technical review by CDSCO
- Expert Committee evaluation (if applicable)
- Approval, licence issuance, and post-marketing surveillance
Pre-submission assessment and gap analysis
The smartest companies begin months before submission.
Our consulting practice typically starts with a Regulatory Gap Audit—matching the client’s data package against NDCTR expectations.
A good pre-submission plan should cover:
- Clarifying “new drug” classification.
- Confirming local data requirements.
- Mapping the dossier to CTD (Common Technical Document) format.
- Verifying GMP certificates for all sites.
- Conducting a pre-submission meeting with CDSCO (optional but highly recommended).
Filing Form 44 and required documentation
Form 44 is the core submission form for new drugs, biologics, and fixed-dose combinations.
It should be accompanied by:
- Cover letter and index.
- Manufacturing licence or import licence.
- Detailed CMC modules (Modules 2–3).
- Clinical trial data (Modules 4–5).
- Stability, impurity, and validation data.
- Ethics Committee approvals for local clinical studies.
CDSCO reviews administrative completeness first. Missing annexures or unsigned forms can delay file registration.
Technical review and expert committee evaluation
Once the file passes administrative screening, the Subject Expert Committee (SEC) or New Drug Advisory Committee (NDAC) reviews the technical dossier.
They evaluate:
- Pharmacology and toxicology results.
- Clinical data integrity.
- Comparative safety and efficacy.
- Quality attributes and process validation.
Applicants may be invited to present clarification or bridging data. A clear, concise response package often accelerates final approval.
CDSCO approval and post-marketing obligations
After technical clearance, CDSCO issues an approval letter, sometimes with conditions—typically a Phase IV post-marketing study or periodic safety reporting (PSUR).
A product’s life cycle is monitored continuously. Every approval implies ongoing pharmacovigilance obligations.
Key documents and forms required for cdsco new drug approval
- Form 44 (application form)
- Treasury challan for fee payment
- Comprehensive dossier (CTD structure preferred)
- Manufacturing licence or import licence copy
- Pre-clinical and clinical study reports
- Stability and validation data
- GMP certificates
- Ethics Committee and investigator approvals
- Draft package insert and label artwork
- Undertaking for adverse event reporting
Understanding CDSCO Form 44: purpose, content and best practices
Form 44 is more than a form—it’s the legal face of your submission. Every detail matters.
Common mistakes we observe include: mismatched company names, missing authorisation letters, or outdated formats.
Best practices:
- Always download the latest version from CDSCO’s portal.
- Mention product category clearly (new molecule / FDC / biologic).
- Attach all annexures in order.
- Provide justification letters where data exemptions apply.
A complete and accurate Form 44 signals regulatory maturity—it’s the first impression your file makes.
How Indian Clinical Data Strengthens Your cdsco new drug approval Application
India-specific evidence is a recurring theme in cdsco new drug approval.
When a drug already has foreign trial data, CDSCO may accept it with a bridging study—usually a smaller clinical trial in Indian subjects to confirm safety and pharmacokinetics.
Bridging studies are particularly important when:
- Ethnic variability may affect response.
- The global trial lacked Indian participants.
- Dosage regimens differ from Indian practice.
CDSCO assesses whether global data is “scientifically and ethically transferable.”
A concise bridging protocol, approved by an Ethics Committee, often satisfies this requirement without redoing full-scale Phase III trials
Timelines and approval stages: how long does CDSCO take?
While NDCTR sets indicative timeframes, actual durations depend on dossier quality.
| Stage | Approx. Duration |
| Pre-submission & data readiness | 1–2 months |
| File submission and screening | 4–6 weeks |
| Technical & committee review | 6–9 months |
| Query resolution cycles | 1–3 months |
| Final approval & licence issuance | Variable (total 9–15 months) |
A strong file and proactive responses can shorten timelines substantially.
How Recent CDSCO Reforms Are Transforming New Drug Approval Timelines
Between 2022 and 2024, CDSCO introduced key reforms:
- Fast-track review for life-saving or national priority drugs.
- Simplified import licensing for globally approved molecules.
- Digital portal integration under SUGAM 2.0 for online tracking.
These changes help genuine innovators move faster—provided documentation is transparent and structured.
How to Overcome a Regulatory Hold During cdsco new drug approval
A multinational vaccine manufacturer faced a technical hold because CDSCO required local immunogenicity data.
Our team proposed a limited bridging study in 50 Indian subjects, aligned with WHO sample size norms.
By completing the study within 90 days and submitting interim safety results, the hold was lifted, and approval came within six months.
Common mistakes that delay cdsco new drug approval (and how to avoid them)
- Submitting incomplete annexures.
- Ignoring pre-submission meetings.
- Overreliance on foreign data.
- Missing signatures on CRFs or EC letters.
- Under-documenting manufacturing validations.
Avoiding these five pitfalls alone can shave months off your approval timeline.
Post-approval responsibilities and pharmacovigilance requirements
Once approved, the sponsor must maintain vigilance:
- Periodic Safety Update Reports (PSURs) every six months for the first two years.
- Phase IV studies when required.
- Expedited reporting of serious adverse events (SAEs).
- Label updates in response to safety findings.
Failure to comply can result in suspension or withdrawal of approval.
How to plan your CDSCO pre-submission meeting
A pre-submission meeting with CDSCO offers strategic value.
Prepare a concise agenda:
- Define your “new drug” classification.
- Present a summary of data generated so far.
- Ask clear questions on bridging requirements.
- Record official feedback for internal use.
Such meetings show transparency and can prevent future holds.
Conclusion
A successful cdsco new drug approval is the outcome of disciplined documentation and proactive communication.
The process rewards clarity, completeness, and local relevance. Whether you’re filing your first IND or expanding a global portfolio, building compliance into every stage—from trial design to CMC validation—sets you apart.
Our regulatory consultants work alongside Indian manufacturers and global innovators to plan, file, and defend CDSCO submissions efficiently.
If you’re preparing for your next cdsco new drug approval, connect with our compliance desk today for a dossier audit or pre-submission strategy call.
Frequently Asked Questions
What does new drug approval by cdsco mean?
It refers to the process followed in which the Central Drugs Standard Control Organisation (CDSCO) grants approval to a drug discovered by a manufacturer after a review of safety, efficacy, quality data under the NDCTR 2019.
What form is required for new drug approval by cdsco?
The applicant needs to file Form 44 with a complete dossier, which includes clinical data, stability data or reports, manufacturing, and GMP certificates.
How long does it take to get a new drug approved by cdsco?
Usually around 9 to 15 months, based on the completeness and response to any queries needed by the committee and review processes.
What documents will I need?
You will need Form 44; a CTD dossier; clinical trial report(s); GMP certificates; ethics approval(s); and a draft package insert.
Are clinical trials required for cdsco new drug approval?
Clinical trials are always necessary unless the global dataset can bridge the information in conjunction with Indian studies or on the basis of scientific comparability.
What happens after cdsco new drug approval?
Post-marketing surveillance is initiated - companies report to the CDSCO using Periodic Safety Update Reports (PSURs) and report adverse events as required based on the Official Drugs (Pharmacovigilance) Rules.
